Krystal Biotech, Inc.
NASDAQ: KRYS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Krish S. Krishnan
- Employees
- 275
- Headquarters
- Pittsburgh, United States
- IPO year
- 2017
- Market cap
- $10.3B
- Website
- https://www.krystalbio.com
Loading KRYS…
Loading profile data…Frequently asked questions about KRYS
What does Krystal Biotech, Inc. (KRYS) do?
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bull...
Where does KRYS trade?
Krystal Biotech, Inc. (KRYS) trades on the NASDAQ Global Market.
What sector is KRYS in?
Krystal Biotech, Inc. (KRYS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Krystal Biotech, Inc.?
Krish S. Krishnan is the chief executive officer of Krystal Biotech, Inc. (KRYS).
Where is Krystal Biotech, Inc. headquartered?
Krystal Biotech, Inc. is headquartered in United States.
Does KRYS pay a dividend?
Krystal Biotech, Inc. (KRYS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KRYS go public?
Krystal Biotech, Inc. (KRYS) completed its initial public offering in 2017.